Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults with Moderate Renal Function Impairment
© 2015 The Author 2015. Background. The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient. Using a new TDF formulation, we compared the pharmacokinetics of the standard dose with a dose of 150 mg o...
Saved in:
相似書籍
-
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults with Moderate Renal Function Impairment
由: Tim R. Cressey, et al.
出版: (2018) -
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
由: Tim R. Cressey, et al.
出版: (2020) -
Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors
由: Geoffroy Liegeon, et al.
出版: (2019) -
Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
由: David V. Glidden, et al.
出版: (2018) -
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Temofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Temofovir Disoproxil Fumarate Monotherapy
由: Vera E. Bukkems, et al.
出版: (2020)